Zoetis stock seen as undervalued despite short-term challenges in pet demand and competition.

Zoetis, a leading animal health company, faces short-term challenges including weaker U.S. companion animal demand, increased competition, and margin pressure from promotions and rebates. However, long-term growth is expected due to trends like pet humanization, international expansion, a strong R&D pipeline, and growth in diagnostics. Management remains confident, signaling recovery through increased share buybacks and disciplined capital allocation. The stock is considered undervalued based on discounted cash flow valuation, making it a buy despite current headwinds.

Zoetis shares trade at USD 73.31 on Pluang as of Sep 17, 2026 17:02 WIB, showing a modest 0.41% gain for the day. The stock's market cap stands at $30.34 billion, with a dividend yield of 2.89%. Investors typically hold Zoetis for about 66 days on the platform, reflecting steady interest despite recent challenges.